Mark Socinski introduce a new pathway tool for USA designed to help clinicians

(1:51)

Interview with Mark Socinski, MD

(3:21)

Mark Socinski, MD: Evaluating Theraputic Options

(4:54)

Patient Success Stories: Metastatic Lung Adenocarcinoma, Mark Socinski MD

(3:59)

Concurrent Chemoradiation Therapy (cCRT): The Standard of Care in Unresectable Stage III NSCLC

(13:24)

Perseverance in molecular testing pays off – Looking beyond the obvious mutations in NSCLC

(23:25)

How Breakthroughs in Immunotherapy are Helping Non-Small Cell Lung Cancer Patients Live Longer

(2:15)

Hang in There | A Song Dedicated to those Fighting Cancer

(5:34)

Chill Out with AVSC's Fresh Menthol Permafrost Shave Soap!

(24:44)

Toxicities Associated with Anti–PD-1 Immunotherapy

(11:40)

Why Palliative Care During Concurrent CRT in Stage III NSCLC Curative Intent Setting is Beneficial

(6:32)

Experts Discuss the Importance of Coordinating and Planning Concurrent CRT in Stage III NSCLC

(7:29)

How Long Do You Live With Stage 4 Lung Cancer? | Lung Foundation Australia

(1:41)

Cancer Immunotherapy - PD-1 and PD-L1

(4:)

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

(1:2)

Mark Socinski, MD: Lacking Actionable Mutations in NSCLC

(2:21)

Communication and Coordination Between MedOnc and RadOnc Is Key for cCRT in Stage III NSCLC

(4:15)

Interview with Dr. Mark A. Socinski, MD

(4:23)

Chemotherapy Techniques to Help Unresectable Stage III NSCLC Patients Get Through Concurrent CRT

(2:20)

Checkpoint Inhibitors in Malignant Pleural Mesothelioma

(5:58)

Chemotherapy Options for Improved Concurrent CRT Regimens for Stage III NSCLC

(5:14)

Post Concurrent Chemoradiation Therapy: Management of Patients Who Do Not Progress

(10:12)

November 19, 2018 | Lung Cancer Awareness Month, Dr. Mark Socinski

(58)

Progression of ALK+ NSCLC

(5:14)

GRACEcast-111_Lung-Cancer_ASCO 2012 LC Highlights: Dr. Socinski on TAILOR Trial in Advanced NSCLC

(7:9)

Immune Checkpoint Inhibitors in Small-Cell Lung Cancer

(4:47)

Dr. Socinski on Improvements to Immunotherapy for Prostate Cancer

(1:21)

Entrevista al Dr. Mark Socinski

(2:19)

GRACEcast-112_Lung-Cancer_ASCO 2012 LC Highlights: Dr. Socinski on Key Trials in Small Cell LC

(8:6)